BYSI News and Press, BeyondSpring Inc. From 09/20/21

Study met the primary endpoint showing statistically significant improvement in overall survival (OS) for the combination (DP) vs. docetaxel (D). Study met key secondary endpoints showing statistically significant improvement for DP vs. D in ORR, PFS, and 24- and 36-month OS r...

BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning in early 2022. On Monday morning 9/20/21, BeyondSpring will present at ESMO late brea...

NEW YORK, Sept. 16, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of innovative cancer therapeutics, today announced new positive data on plinabul...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

BeyondSpring Inc. (BYSI) Q2 2021 Earnings Conference Call September 10, 2021 8:00 AM ET Company Participants Monique Kosse - LifeSci Advisors Lan Huang - Co-Founder, Chairman and Chief Executive Officer Ramon Mohanlal - EVP, Research & Development and Chief Medical Officer Richard Daly - ...

Image source: The Motley Fool. BeyondSpring inc (NASDAQ: BYSI) Q2 2021 Earnings Call Sep 10, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: BeyondSpring inc (BYSI) Q2 2021 Earnings Call Transcript

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced its financial results for the second...

BYSI, KR, TIGR For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Friday's open

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or &#x...

NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will present at and participate in the Morgan Stanl...